Inventor · disambiguated record
Charles Paulding
Also filed as: PAULDING CHARLES
5 granted patents·11 pending applications·0 citations·filing 2002–2025
63Inventor score
Top patents by PatentIndex Score
16 records- 0169US12116622B2Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGFREGENERON PHARMA·Filed 2021·Granted Oct 15, 2024·0 cites·28 claims
- 0268US2024404627A1Systems and Methods for Correcting for Noise and Systemic Variations in Sequencing DataREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0368US2024029897A1Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VEGFREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0463US12378557B2Treatment of sepsis with PCSK9 and LDLR modulatorsREGENERON PHARMA·Filed 2021·Granted Aug 5, 2025·0 cites·6 claims
- 0563US2024310383A1Proteomic Risk Score For Osteoarthritis (OA)REGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0662US11519020B2Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGFREGENERON PHARMA·Filed 2018·Granted Dec 6, 2022·0 cites·16 claims
- 0759US2023348608A1Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk ScoreREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0857US12264366B2Genome-based methods for reducing cardiovascular riskREGENERON PHARMA·Filed 2020·Granted Apr 1, 2025·0 cites·7 claims
- 0957US2023151426A1Reticulocalbin-3 (RCN3) Variants And Treatment Of Asthma With Interleukin-4 Receptor Alpha (IL4R) AntagonistsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1056US2023272062A1Treatment Of Lung Disease Based Upon Stratification Of Polygenic Score Relating To Response To A Therapeutic AgentREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1156US2023272096A1Treatment Of Lung Disease Based Upon Stratification Of Polygenic Risk Score For Interleukin 33 (IL-33)REGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1256US2025257406A1Genome-Based Methods For Reducing Cardiovascular RiskREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1354US11769597B2Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGFREGENERON PHARMA·Filed 2018·Granted Sep 26, 2023·0 cites·20 claims
- 1438US2006041111A1Dock 3 tumor suppressor geneYAJNIK VIJAY·Filed 2002·Application pending·0 cites
- 1537US2011144206A1Use of a cox-2 inhibitor for the treatment of a cox-2 dependent disorder in a patient not carrying hla alleles associated with hepatotoxicityLEWITZKY STEVEN·Filed 2009·Application pending·0 cites
- 1633US2013052644A1Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS)GOMEZ-MANCILLA BALTAZAR·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Charles Paulding files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →